E. Muslimova

Infigratinib in children with achondroplasia: the PROPEL and PROPEL 2 studies

M. Irving, F. Santos-Simarro, J. Hoover-Fong, 2022, Therapeutic advances in musculoskeletal disease.

Durability of treatment response after 1 year of therapy with seladelpar in patients with primary biliary cholangitis (PBC): final results of an international phase 2 study

S. Bergheanu, T. Hassanein, B. Bacon, 2020, Journal of Hepatology.